Preventives or remedies for psoriasis containing as the active ingredient il-6 antagonist

• US 20040028681A1
• Filed: 04/24/2003
• Published: 02/12/2004
• Est. Priority Date: 10/25/2000
• Status: Active Grant

• Current Assignee: Chugai Seiyaku Kabushiki Kaisha (Roche Holding AG)
• Original Assignee: Chugai Seiyaku Kabushiki Kaisha (Roche Holding AG)
• Inventors: Akamatsu, Kenichi, Nishimoto, Norihiro, Sugimoto, Masamichi, Ito, Hiroaki, Yoshizaki, Kazuyuki, Kitamura, Hidetomo, Kishimoto, Tadamitsu, Shimaoka, Shin
• Granted Patent: US 7,320,792 B2
• Time in Patent Office: Days
• US Class Current: 424/145.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C07K 16/248 IL-6
• CPC Class Codes: C07K 16/2866 against receptors for cytokines, lymphokines, interferons

Abstract

A preventive and therapeutic agent for psoriasis comprising an interleukin-6 (IL-6) antagonist such as, for example, an antibody against IL-6 receptor.

Claims

1. A preventive or therapeutic agent for psoriasis comprising interleukin-6 (IL-6) antagonist as an active ingredient.

2. The preventive or therapeutic agent according to claim 1, in which the IL-6 antagonist is an antibody against IL-6 receptor.

3. The preventive or therapeutic agent according to claim 2, in which the antibody against IL-6 receptor is a monoclonal antibody against IL-6 receptor.

4. The preventive or therapeutic agent according to claim 3, in which the antibody against IL-6 receptor is a monoclonal antibody against human IL-6 receptor.

5. The preventive or therapeutic agent according to claim 3, in which the antibody against IL-6 receptor is a monoclonal antibody against mouse IL-6 receptor.

6. The preventive or therapeutic agent according to any one of claims 2-5, in which the antibody against IL-6 receptor is a recombinant antibody.

7. The preventive or therapeutic agent according to claim 4, in which the monoclonal antibody against human IL-6 receptor is PM-1 antibody.

8. The preventive or therapeutic agent according to claim 5, in which the monoclonal antibody against mouse IL-6 receptor is MR16-1 antibody.

9. The preventive or therapeutic agent according to any one of claims 2-4, in which the antibody against IL-6 receptor is a chimeric antibody or a humanized antibody against IL-6 receptor.

10. The preventive or therapeutic agent according to claim 9, in which the humanized antibody against IL-6 receptor is a humanized PM-1 antibody.

11. Use of an interleukin-6 (IL-6) antagonist for the production of a preventive and therapeutic agent for psoriasis.

12. The use according to claim 11, in which the IL-6 antagonist is an antibody against IL-6 receptor.

13. The use according to claim 12, in which the antibody against IL-6 receptor is a monoclonal antibody against IL-6 receptor.

14. The use according to claim 13, in which the antibody against IL-6 receptor is a monoclonal antibody against human IL-6 receptor.

15. The use according to claim 13, in which the antibody against IL-6 receptor is a monoclonal antibody against mouse IL-6 receptor.

16. The use according to any one of claims 12-15, in which the antibody against IL-6 receptor is a recombinant antibody.

17. The use according to claim 14, in which the monoclonal antibody against human IL-6 receptor is PM-1 antibody.

18. The use according to claim 15, in which the monoclonal antibody against mouse IL-6 receptor is MR16-1 antibody.

19. The use according to any one of claims 12-14, in which the antibody against IL-6 receptor is a chimeric antibody or a humanized antibody against IL-6 receptor.

20. The use according to claim 19, in which the humanized antibody against IL-6 receptor is a humanized PM-1 antibody.

21. A method of preventing or treating psoriasis comprising administering an interleukin-6 (IL-6) antagonist to a subject.

22. The method according to claim 21, in which the IL-6 antagonist is an antibody against IL-6 receptor.

23. The method according to claim 22, in which the antibody against IL-6 receptor is a monoclonal antibody against IL-6 receptor.

24. The method according to claim 23, in which the antibody against IL-6 receptor is a monoclonal antibody against human IL-6 receptor.

25. The method according to claim 23, in which the antibody against IL-6 receptor is a monoclonal antibody against mouse IL-6 receptor.

26. The method according to any one of claims 22-25, in which the antibody against IL-6 receptor is a recombinant antibody.

27. The method according to claim 24, in which the monoclonal antibody against human IL-6 receptor is PM-1 antibody.

28. The method according to claim 25, in which the monoclonal antibody against mouse IL-6 receptor is MR16-1 antibody.

29. The method according to any one of claims 22-24, in which the antibody against IL-6 receptor is a chimeric antibody or a humanized antibody against IL-6 receptor.

30. The method according to claim 29, in which the humanized antibody against IL-6 receptor is a humanized PM-1 antibody.